EMA keeps famciclovir authorisations unchanged after PSUSA; what 'maintenance' means for PV teams
A PSUSA concluding with 'maintenance' is a quiet outcome, but alongside CMV immunoglobulin and other 19 November safety news it shows where PV workload is really heading.
What happened
On 19 November 2026 the EMA published the outcome of the periodic safety update report single assessment (PSUSA) for famciclovir. The regulatory result is 'maintenance' for nationally authorised products. The EMA notice summarised in our records gives no further detail, so any finding that sits behind the outcome is not yet known from this source.
The same day, the agency published a second PSUSA outcome, for cytomegalovirus immunoglobulin, also recorded as maintenance, with the marketing authorisations to be maintained. Two maintenance outcomes in one day is not a trend, but together they are a useful reminder of what the PSUSA system mostly delivers: confirmation that the benefit-risk balance of established products remains unchanged.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- EMA publishes PSUSA outcome for famciclovir with 'maintenance' regulatory result EMA · Thu 19 Nov 2026
- EMA publishes PSUSA outcome for cytomegalovirus immunoglobulin: marketing authorisations to be maintained EMA · Thu 19 Nov 2026
- FDA creates CBER Safety Council to oversee postmarket safety of biologics FDA CBER · Thu 19 Nov 2026
- React Health recalls 7,533 Luna G3 BPAP devices over incorrect pressure data FDA MedWatch · Thu 19 Nov 2026
- FDA early alert: B. Braun updates Caresite Micro valve instructions over sticking piston FDA MedWatch · Thu 19 Nov 2026
- SÚKL publishes Czech national hemovigilance annual report for 2025 SÚKL · Thu 19 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.